Trials / Terminated
TerminatedNCT02216513
Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | desferrioxamine (DFO) | DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days |
| DRUG | placebo | normal saline IV for 4 hours for 5 consecutive days |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-06-01
- Completion
- 2015-07-01
- First posted
- 2014-08-15
- Last updated
- 2015-07-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02216513. Inclusion in this directory is not an endorsement.